New study clears a pharmacologic hurdle in developing molecularly targeted therapies for AML

New research from Johns Hopkins Kimmel Cancer Center investigators shows why some drugs in clinical trials for treating a form of acute myeloid leukemia (AML) often fail and demonstrates a way to restore their effectiveness.

Generated by Feedzy